Ono
-
Generic drug manufacturers forge alliances in face of tough economic climate
The generic drugs sector’s role as the provider of affordable drugs has widely benefitted public and private health payers keen to control costs. But in the current economic climate, downward pressure on prices is impacting the generic sector, with increases in acquisition and strategic partnering now firmly part of the competitive landscape.
Ono | 28 February 2012
-
Abbott honored with Asian CSR award for leadership in science education
Abbott science education programs advance science learning for children in Asia and around the world.
Ono | 24 October 2011
-
Progenra and Ono Pharmaceutical enter into research collaboration
Progenra will collaborate with Ono to conduct assay development and high throughput screening by using Progenra’s proprietary technology on multiple targets in the ubiquitin pathway.
Ono | 12 October 2011
-
Bristol-Myers Squibb and Ono enter into strategic agreement for anti-PD-1 antibody
Companies also form strategic alliance for the co-development and co-commercialization of ORENCIA (abatacept) in Japan.
Ono | 21 September 2011
-
Shionogi signs agreement to expand its portfolio
Shionogi Inc announced that it has entered into an agreement to acquire all currently marketed products from Victory Pharma Inc, including seven treatments for pain and two for infectious diseases. The products, which are all approved by the Food and…
Ono | 19 July 2011
-
The Asia Foundation honors Dr David Ho at Lotus Leadership Awards
The Asia Foundation and The Lotus Circle honor Dr David Ho, Founding Scientific Director and CEO of the Aaron Diamond AIDS Research Center, for his contributions to the health and well-being of Chinese women and children. According to the foundation,…
Ono | 09 June 2011
-
Physical, socioeconomic and psychological burdens of Psoriasis
According to recent data from a phase three study, the burden faced by psoriasis patients is a growing worldwide concern. Psoriasis is a non-contagious skin disease that affects 80 million people worldwide. It is a common inflammatory skin condit…
Ono | 18 August 2010
-
Amsbio: Easy and Economic Generation of Functional siRNAs
The Turbo Dicer siRNA Generation Kit from Amsbio enables the easy and cost-effective generation of a large number of small interfering Ribonucleic Acid (siRNAs) from full-length target genes. siRNAs are 21- to 23-nucleotide RNA molecules that can …
Ono | 17 May 2010
-
Sloning Strengthens Intellectual Property with US Patent
Sloning, leading supplier of synthetic biology tools was awarded US Patent No, 7,695,906. The former’s enabling platform technology – Slonomics, allows researchers to increase the success rate of their screening for new and optimized therapeutic …
Ono | 06 May 2010
-
Bionomics Announces Trial Results for Antidepressant Drug
Bionomics has announced the final results of its Phase Ia clinical trial of BNC210. The primary objectives of the trial, to evaluate the safety, tolerability and the pharmacokinetics of the drug were met when stage one trial results were reported on …
Ono | 11 March 2010
